This DDR checkpoint decline in subsets of advanced cancers reflects events, such as selection for loss-of-function mutations in the ATM-Chk2 signalling module that activates p53, or selection for mutations in the p53 tumour suppressor itself [17]. This evidence concerns the gene TP53 and neoplasm.